Vascular Biogenics Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) - Fireside Chat Transcript
Good morning, everyone, and welcome back. I am Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with Vascular Biogenics, a clinical stage and, hopefully soon, commercial stage biotech.
Joining us here today is Dror Harats. Dror, Thank you so very much for your time this morning. We really look forward to the discussion. Before we get into a specific Q&A, would you mind perhaps giving us a quick 2- to 3-minute overview of your Company, pipeline and platform?
Sure. Thank you very much, Charles, for having me here. So, we are a late stage biotech company and, as you were saying, we are hopefully going to be soon a commercial company. We are towards the end; we are wrapping up a Phase 3 randomized control big trial, 400 patient trial, which is a registration enabling study in platinum resistant ovarian cancer.
And that's in our lead compound ofra-vec or VB--111, which is based on our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |